BIOQUAL Announces Fiscal Year 2000 Earnings and Declares Dividend.Business Editors ROCKVILLE, Md.--(BUSINESS WIRE)--Aug. 14, 2000 BIOQUAL, Inc. (BIOQUAL) completed its fiscal year on May 31, 2000, in which it had net earnings of $97,246, or $0.11 per share (basic and diluted di·lute tr.v. di·lut·ed, di·lut·ing, di·lutes 1. To make thinner or less concentrated by adding a liquid such as water. 2. To lessen the force, strength, purity, or brilliance of, especially by admixture. ). BIOQUAL's Board of Directors has declared a dividend of $0.03 per share for shareholders of record on September 11, 2000, payable on September 27, 2000. This is the second dividend declared by BIOQUAL. BIOQUAL's base business in government contract work has allowed the Company to explore opportunities in a variety of related disciplines. During the past three years, BIOQUAL has invested a significant percentage of its earnings in evaluating and developing technologies geared toward commercial opportunities. These have included acquisition of technologies suited for immediate marketing, internal research, and development in areas of human and animal therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , reproductive toxicology toxicology, study of poisons, or toxins, from the standpoint of detection, isolation, identification, and determination of their effects on the human body. Toxicology may be considered the branch of pharmacology devoted to the study of the poisonous effects of drugs. , contraceptive contraceptive /con·tra·cep·tive/ (-sep´tiv) 1. diminishing the likelihood of or preventing conception. 2. an agent that so acts. screening, neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their , and animal model development. Statements herein that are not descriptive of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including those set forth in BIOQUAL's Securities and Exchange Commission filings under "Risk Factors", including risks relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the early stage of products under development; uncertainties relating to clinical trial; dependence on third parties' future capital needs; and risks relating to the commercialization, if any of BIOQUAL's proposed products (such as marketing, safety, regulatory, patent, product liability, supply competition, and other risks). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion